€ million |
|
Q2 2025 |
|
Q2 2026 |
|
H1 2025 |
|
H1 2026 |
|||
|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales |
|
10,739 |
|
10,872 |
|
24,477 |
|
24,277 |
|||
Cost of goods sold |
|
(4,364) |
|
(4,540) |
|
(9,989) |
|
(9,772) |
|||
Gross profit |
|
6,375 |
|
6,332 |
|
14,488 |
|
14,505 |
|||
Selling expenses |
|
(3,032) |
|
(3,402) |
|
(6,191) |
|
(6,566) |
|||
Research and development expenses |
|
(1,408) |
|
(1,518) |
|
(2,866) |
|
(2,937) |
|||
General administration expenses |
|
(513) |
|
(561) |
|
(1,061) |
|
(1,093) |
|||
Other operating income |
|
702 |
|
545 |
|
907 |
|
1,355 |
|||
Other operating expenses |
|
(2,111) |
|
(569) |
|
(2,940) |
|
(909) |
|||
EBIT1 |
|
13 |
|
827 |
|
2,337 |
|
4,355 |
|||
Equity-method income (loss) |
|
(25) |
|
(14) |
|
(27) |
|
(1) |
|||
Financial income |
|
81 |
|
120 |
|
173 |
|
247 |
|||
Financial expenses |
|
(495) |
|
(612) |
|
(1,079) |
|
(1,291) |
|||
Financial result |
|
(439) |
|
(506) |
|
(933) |
|
(1,045) |
|||
Income before income taxes |
|
(426) |
|
321 |
|
1,404 |
|
3,310 |
|||
Income taxes |
|
236 |
|
(92) |
|
(290) |
|
(314) |
|||
Income after income taxes |
|
(190) |
|
229 |
|
1,114 |
|
2,996 |
|||
of which attributable to noncontrolling interest |
|
9 |
|
10 |
|
14 |
|
14 |
|||
of which attributable to Bayer AG stockholders (net income) |
|
(199) |
|
219 |
|
1,100 |
|
2,982 |
|||
|
|
|
|
|
|
|
|
|
|||
€ |
|
|
|
|
|
|
|
|
|||
Earnings per share |
|
|
|
|
|
|
|
|
|||
Basic |
|
(0.20) |
|
0.23 |
|
1.12 |
|
3.04 |
|||
Diluted |
|
(0.20) |
|
0.23 |
|
1.12 |
|
3.04 |
|||
|
|||||||||||